✦ LIBER ✦

On scheduling with earliest starts and due dates on a group of identical machines

✍ Scribed by Charles Tilquin

Publisher: John Wiley and Sons
Year: 1975
Tongue: English
Weight: 499 KB
Volume: 22
Category: Article
ISSN: 0894-069X
DOI: 10.1002/nav.3800220411

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Scheduling with earliest start and due d

Scheduling with earliest start and due date constraints on multiple machines

✍ Paul Bratley; Michael Florian; Pierre Robillard 📂 Article 📅 1975 🏛 John Wiley and Sons 🌐 English ⚖ 441 KB

Due-date assignment and early/tardy sche

Due-date assignment and early/tardy scheduling on identical parallel machines

✍ Prabuddha De; Jay B. Ghosh; Charles E. Wells 📂 Article 📅 1994 🏛 John Wiley and Sons 🌐 English ⚖ 871 KB

Scheduling jobs, with exponentially dist

Scheduling jobs, with exponentially distributed processing times, on two machines of a flow shop

✍ Andrew A. Cunningham; Sujit K. Dutta 📂 Article 📅 1973 🏛 John Wiley and Sons 🌐 English ⚖ 450 KB

Mergers and group status: the impact of

Mergers and group status: the impact of high, low and equal group status on identification and satisfaction with a company merger, experienced controllability, group identity and group cohesion

✍ Peter Fischer; Tobias Greitemeyer; Suat Ilkay Omay; Dieter Frey 📂 Article 📅 2007 🏛 John Wiley and Sons 🌐 English ⚖ 129 KB 👁 2 views

Treatment of advanced adenocarcinomas of

Treatment of advanced adenocarcinomas of the exocrine pancreas and the gallbladder with 5-fluorouracil, high dose levofolinic acid and oral hydroxyurea on a weekly schedule: Results of a multicenter study of the Southern Italy Oncology Group (G.O.I.M.)

✍ Vittorio Gebbia; Evaristo Majello; Antonio Testa; Giuseppe Pezzella; Serravezza 📂 Article 📅 1996 🏛 John Wiley and Sons 🌐 English ⚖ 787 KB

## BACKGROUND. To date there is no established chemotherapeutic treatment for patients with unresectable locally advanced and/or metastatic carcinomas of the exocrine pancreas or the gallbladder. A multicenter Phase I1 trial has been performed by the Southern Italy Oncology Group with the aim of e